Notice2024-05880
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 20, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 55 (Wednesday, March 20, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 55 (Wednesday, March 20, 2024)]
[Notices]
[Page 19855]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-05880]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Peter Tung at 240-669-5483 or
<a href="/cdn-cgi/l/email-protection#95e5f0e1f0e7bbe1e0fbf2d5fbfcfdbbf2fae3"><span class="__cf_email__" data-cfemail="adddc8d9c8df83d9d8c3caedc3c4c583cac2db">[email protected]</span></a>. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852: tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
Licensing information and copies of the patent applications listed
below may be obtained by communicating with the Technology Transfer and
Intellectual Property Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852 by
contacting Peter Tung at 240-669-5483 or <a href="/cdn-cgi/l/email-protection#1e6e7b6a7b6c306a6b70795e70777630797168"><span class="__cf_email__" data-cfemail="b4c4d1c0d1c69ac0c1dad3f4dadddc9ad3dbc2">[email protected]</span></a>. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished patent applications related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants
for Malaria Vaccine Development Using SPEEDesign Technology
Description of Technology
The technology includes modifying the Plasmodium falciparum Pfs48/
45 Domain III protein sequence to enhance its stability and efficacy to
aid in malaria vaccine development. This approach successfully
overcomes previous production challenges by increasing the
thermostability of the antigen and eliminating the need for additional
modifications that could impair vaccine effectiveness. Crucially, the
technology maintains the essential neutralizing epitope of Pfs48/45,
ensuring its effectiveness in preventing malaria transmission as a
transmission-blocking vaccine. Developed using the SPEEDesign program,
these novel protein variants show increased stability and a more robust
transmission blocking response than wild-type proteins. The potential
applications of this technology are providing a more stable and
effective vaccine, potentially reducing the incidence of malaria and
leading to improved health outcomes.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
<bullet> This malaria vaccine technology offers competitive
advantages by providing increased thermostability and enhanced immune
response without the need for efficacy-reducing modifications,
potentially revolutionizing malaria prevention with more effective and
stable vaccine options.
Competitive Advantages
<bullet> The development of more effective and stable malaria
vaccines offers improved prevention strategies in regions affected by
this disease and significantly contributing to global health
initiatives.
Development Stage
Pre-Clinical
Inventors: Niraj Tolia, Ph.D., Thayne Dickey, Ph.D., all of NIAID.
Publications
Intellectual Property: HHS Reference No. E-030-2023-0-US-01, US
Provisional Application No. 63/476,897, filed on December 22, 2022; HHS
Reference No. E-030-2023-0-PC-01, PCT Application No. PCT/US2023/
085849, filed on December 22, 2023
Licensing Contact: To license this technology, please contact Peter
Tung at 240-669-5483 or <a href="/cdn-cgi/l/email-protection#c7b7a2b3a2b5e9b3b2a9a087a9aeafe9a0a8b1"><span class="__cf_email__" data-cfemail="2555405140570b51504b42654b4c4d0b424a53">[email protected]</span></a>, and reference E-030-2023.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. For collaboration
opportunities, please contact Peter Tung at 240-669-5483 or
<a href="/cdn-cgi/l/email-protection#3343564756411d47465d54735d5a5b1d545c45"><span class="__cf_email__" data-cfemail="69190c1d0c1b471d1c070e29070001470e061f">[email protected]</span></a>.
Dated: March 14, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-05880 Filed 3-19-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on March 20, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.